Changes in the Number of Continuation Patents on Drugs Approved by the FDA
JAMA · 01.08.2023 · 330 (5) · 469
DOI: 10.1001/jama.2023.11525 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 01.08.2023. Verfasst von S Sean Tu und 3 weiteren Autor:innen. Beteiligte Einrichtung: West Virginia University College of Law, Morgantown. Hauptthemen laut MEDLINE: Drug Costs, Economic Competition, Patents as Topic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
This study assesses the frequency of continuation patents on brand-name drugs approved by the US Food and Drug Administration from 2000 to 2015.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- West Virginia University College of Law, Morgantown.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
- Sanford School of Public Policy, Duke University, Durham, North Carolina.
Förderung
- NHLBI NIH HHS
Zitieren
APA
Tu, S. S., Kesselheim, A. S., Wetherbee, K., & Feldman, W. B. (2023). Changes in the Number of Continuation Patents on Drugs Approved by the FDA. JAMA, 330(5), 469. https://doi.org/10.1001/jama.2023.11525
Vancouver
Tu SS, Kesselheim AS, Wetherbee K, Feldman WB. Changes in the Number of Continuation Patents on Drugs Approved by the FDA. JAMA. 2023;330(5):469. doi:10.1001/jama.2023.11525
BibTeX
@article{Tu2023,
author = {Tu, S Sean and Kesselheim, Aaron S and Wetherbee, Kathrine and Feldman, William B},
title = {Changes in the Number of Continuation Patents on Drugs Approved by the FDA},
journal = {JAMA},
year = {2023},
volume = {330},
number = {5},
pages = {469},
doi = {10.1001/jama.2023.11525}
}
EUVIMED